NPTX2 is associated with neoadjuvant therapy response in rectal cancer

Karagkounis, Georgios; Thai, Leo; DeVecchio, Jennifer; Gantt, Gerald; Duraes, Leonardo; Pai, Rish K.; Kalady, Matthew F.

doi:10.1016/j.jss.2015.12.042

Cited by 14 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gantt et al analyzed gene expression profiles of pre-treatment tumor biopsy specimens from 33 rectal cancer patients using cDNA microarrays [54]. Neuronal pentraxin II ( NPTX2 ), one of the most differently expressed gene in the datasets, was recently validated using quantitative real time PCR in an independent set of tumor specimens from 40 rectal cancer patients in which decreased NPTX2 gene expression levels was associated with improved response to nCRT and prognosis [55]. …”

Section: Molecular Biomarkers In Tumor Tissuesmentioning

confidence: 99%

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Dayde

Tanaka

Jain

et al. 2017

IJMS

136

141

View full text Add to dashboard Cite

Abstract:The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation (nCRT) followed by radical surgery. Response to nCRT varies among patients and pathological complete response is associated with better outcome. However, there is a lack of effective methods to select rectal cancer patients who would or would not have a benefit from nCRT. The utility of clinicopathological and radiological features are limited due to lack of adequate sensitivity and specificity. Molecular biomarkers have the potential to predict response to nCRT at an early time point, but none have currently reached the clinic. Integration of diverse types of biomarkers including clinicopathological and imaging features, identification of mechanistic link to tumor biology, and rigorous validation using samples which represent disease heterogeneity, will allow to develop a sensitive and cost-effective molecular biomarker panel for precision medicine in rectal cancer. Here, we aim to review the recent advance in tissue-and blood-based molecular biomarker research and illustrate their potential in predicting nCRT response in rectal cancer.

show abstract

Section: Molecular Biomarkers In Tumor Tissuesmentioning

confidence: 99%

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Dayde

Tanaka

Jain

et al. 2017

IJMS

136

141

View full text Add to dashboard Cite

show abstract

“…We furtherly confirmed the obvious overexpression of NPTX2 in our clinical human EOC tissues and cultured cell lines. In order to find the possible role of NPTX2 on EOC, we first searched the available literature about the roles of NPTX2 in malignant tumors and NPTX2 was reported mainly participated in five cancers, including glioma, pancreaticobiliary cancer, colorectal cancer, renal cell carcinoma and neuroblastoma (16)(17)(18)(19)(20)(21). However, NPXT2 plays a contradictory role in those tumors.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia

Han

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundEpithelial ovarian cancer (EOC) is the main subtype of ovarian cancer and shows an aggressive phenotype and poor prognosis. Neuronal pentraxin II (NPTX2) is a member of the neuronal pentraxin family and plays a contradictory role in different tumors. However, there has been no report about the possible role and effect of NPTX2 in EOC.MethodsBioinformatics analysis, qPCR, western blotting and immunohistochemistry were used to detect the expression of NPTX2 in EOC. Lentivirus-based transfection for NPTX2 overexpression or knockdown was performed on the EOC cell lines A2780, HEY, SKOV3 and OVCAR-3. The effect of NPTX2 on the malignant phenotype of EOC was examined through methods of MTS assay, Edu assay, transwell assay, western blotting analysis, qPCR analysis, luciferase reporter assay and xenograft experiment.ResultsEOC tissues showed higher NPTX2 expression than the normal tissues with poor prognosis. NPTX2 overexpression can promote the proliferation, invasion, migration and tumorigenesis of EOC via IL6-JAK2/STAT3 signaling pathway. Moreover, hypoxia-inducible factor-1(HIF-1) can promote the transcription and expression of NPTX2 under the hypoxic environment. NPTX2 knockdown abolished the hypoxia-induced malignant phenotypes in ECO.ConclusionsThe above results suggest that NPTX2 may play a novel role in ovarian cancer’s malignant phenotype and act as a promising treatment target for EOC molecular therapy.

show abstract

“…In order to nd the possible role of NPTX2 on EOC, we rst searched the available literature about the roles of NPTX2 in malignant tumors and NPTX2 was reported mainly participated in ve cancers, including glioma, pancreaticobiliary cancer, colorectal cancer, renal cell carcinoma and neuroblastoma [16][17][18][19][20][21]. However, NPXT2 plays a contradictory role in those tumors.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of NPTX2 Promotes Malignant Phenotypeof Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia

Han

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Epithelial ovarian cancer(EOC) is the main subtype of ovarian cancer and shows an aggressive phenotype and poor prognosis. Neuronal pentraxin II (NPTX2)is a member of the neuronal pentraxin family and plays a contradictory role in different tumors. However, there has been no report about the possible role and effect of NPTX2 in EOC.Methods: Bioinformatics analysis, qPCR, western blotting and immunohistochemistry were used to detect the expression of NPTX2 in EOC. Lentivirus-based transfection for NPTX2 overexpression or knockdown was performed on the EOC cell lines A2780, HEY, SKOV3 and OVCAR-3. The effect of NPTX2 on the malignant phenotype of EOC was examined through methods of MTS assay, Edu assay, transwell assay, western blotting analysis, qPCR analysis, luciferase reporter assay and xenograft experiment.Results: EOC tissues showed higher NPTX2 expression than the normal tissues with poor prognosis. NPTX2 overexpression can promote the proliferation, invasion, migration and tumorigenesis of EOC via IL6-JAK2/STAT3 signaling pathway. Moreover, hypoxia-inducible factor-1(HIF-1) can promote the transcription and expression of NPTX2 under the hypoxic environment.Conclusions: The above results suggest that NPTX2 may play a novel role in ovarian cancer's malignant phenotype and act asa promising treatment target for EOC moleculartherapy.

show abstract

NPTX2 is associated with neoadjuvant therapy response in rectal cancer

Cited by 14 publications

References 22 publications

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer

Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia

Overexpression of NPTX2 Promotes Malignant Phenotypeof Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia

Contact Info

Product

Resources

About